Combined use of prostate-specific antigen density and PI-RADS score to optimize prostate biopsy strategy

Introduction: We aimed to compare detection rates of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) between MRI-targeted and transrectal ultrasound (TRUS)-guided systematic transrectal biopsy, and to evaluate prostate-specific antigen (PSA) density (PSAD) as a tool to refine biopsy strategies and reduce unnecessary systematic biopsies. Materials and methods: We retrospectively reviewed 630 biopsy-naïve men who underwent combined MRI-targeted and systematic prostate biopsy in 2023. The mean age was 67.5 years, mean PSA was 6.69 ng/mL, and mean prostate volume was 48.4 cm 3 . Patients were stratified into four PSAD categories: <0.10, 0.10–<0.15, 0.15–<0.20, and ≥0.20 ng/mL/cm 3 . Cancer detection rates were assessed according to biopsy modality, Prostate Imaging-Reporting and Data System (PI-RADS) score, and PSAD. Multivariable logistic regression analysis was performed to identify predictors of csPCa. Results: Overall, PCa was detected in 78.1% (492/630) of patients, of whom 87.0% (428/492) had csPCa. Increasing PSAD was associated with csPCa and a greater number of positive biopsy cores ( p < 0.001). In the multivariable analysis, PSAD remained an independent predictor of csPCa (odds ratio [OR] 3.87, p < 0.001). PI-RADS score was also independently associated with higher-grade disease. PSAD was significantly correlated with PI-RADS score. Among men with PI-RADS 3 lesions, patients with PSAD ≥ 0.20 ng/mL/cm 3 demonstrated 8.5-fold higher odds of csPCa compared with those with PSAD < 0.10 ng/mL/cm 3 . Systematic biopsy consistently detected additional csPCa that would have been missed by targeted biopsy alone across all PSAD strata. Conclusions: PSAD is an independent predictor of PCa and csPCa and complements PI-RADS scoring for biopsy risk stratification, especially for PI-RADS 3 lesions. Systematic biopsy continues to provide additional diagnostic yield beyond MRI-targeted biopsy alone. These findings support the continued use of supplemental sampling in conjunction with MRI-targeted biopsy while highlighting the need for prospective studies to determine whether less extensive approaches, such as targeted plus perilesional sampling, can provide comparable diagnostic performance.

Authors

Publication Details

Journal
Academia Medicine and Health
Published
2026-11-13
DOI
https://doi.org/10.20935/acadmedhealth8636
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Combined use of prostate-specific antigen density and PI-RADS score to optimize prostate biopsy strategy

Dharam M. Ramnani, Yousif M. Shakroo, Junqi Qian, Fadi M. Shakroo
6 links
Academia Medicine and Health
Prostate Cancer Diagnosis and Treatment
article

Combined use of prostate-specific antigen density and PI-RADS score to optimize prostate biopsy strategy

Dharam M. Ramnani, Yousif M. Shakroo, Junqi Qian, Fadi M. Shakroo
article en

Abstract

Introduction: We aimed to compare detection rates of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) between MRI-targeted and transrectal ultrasound (TRUS)-guided systematic transrectal biopsy, and to evaluate prostate-specific antigen (PSA) density (PSAD) as a tool to refine biopsy strategies and reduce unnecessary systematic biopsies. Materials and methods: We retrospectively reviewed 630 biopsy-naïve men who underwent combined MRI-targeted and systematic prostate biopsy in 2023. The mean age was 67.5 years, mean PSA was 6.69 ng/mL, and mean prostate volume was 48.4 cm 3 . Patients were stratified into four PSAD categories: <0.10, 0.10–<0.15, 0.15–<0.20, and ≥0.20 ng/mL/cm 3 . Cancer detection rates were assessed according to biopsy modality, Prostate Imaging-Reporting and Data System (PI-RADS) score, and PSAD. Multivariable logistic regression analysis was performed to identify predictors of csPCa. Results: Overall, PCa was detected in 78.1% (492/630) of patients, of whom 87.0% (428/492) had csPCa. Increasing PSAD was associated with csPCa and a greater number of positive biopsy cores ( p < 0.001). In the multivariable analysis, PSAD remained an independent predictor of csPCa (odds ratio [OR] 3.87, p < 0.001). PI-RADS score was also independently associated with higher-grade disease. PSAD was significantly correlated with PI-RADS score. Among men with PI-RADS 3 lesions, patients with PSAD ≥ 0.20 ng/mL/cm 3 demonstrated 8.5-fold higher odds of csPCa compared with those with PSAD < 0.10 ng/mL/cm 3 . Systematic biopsy consistently detected additional csPCa that would have been missed by targeted biopsy alone across all PSAD strata. Conclusions: PSAD is an independent predictor of PCa and csPCa and complements PI-RADS scoring for biopsy risk stratification, especially for PI-RADS 3 lesions. Systematic biopsy continues to provide additional diagnostic yield beyond MRI-targeted biopsy alone. These findings support the continued use of supplemental sampling in conjunction with MRI-targeted biopsy while highlighting the need for prospective studies to determine whether less extensive approaches, such as targeted plus perilesional sampling, can provide comparable diagnostic performance.

Academia Medicine and HealthVol. 3(4)
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon